Related Experiment Video
Updated: Mar 12, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment
C S Voican1, O Mir2, P Loulergue3
1Gastro-Enterology and Digestive Oncology Unit, Cochin Teaching Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris.
Hepatitis B virus (HBV) reactivation is a risk during cancer treatment. Screening and antiviral therapy can prevent HBV reactivation in patients with solid tumors receiving chemotherapy.
Area of Science:
- Hepatology
- Oncology
- Infectious Diseases
Background:
- Hepatitis B virus (HBV) reactivation is a known risk in patients with hematological malignancies undergoing chemotherapy.
- Data on HBV reactivation risk and management in patients with solid tumors receiving systemic therapy is limited.
Purpose of the Study:
- To assess the risk of HBV reactivation in patients with solid tumors undergoing systemic treatment.
- To provide recommendations for HBV infection management in this patient population.
Main Methods:
- A PubMed search was conducted for publications from January 1990 to May 2016.
- Search terms included 'hepatitis B reactivation' and 'chemotherapy', as well as 'hepatitis B' combined with International Non-proprietary Names of common solid tumor chemotherapy drugs.
Main Results:
- Most anticancer drugs used for solid tumors can induce HBV reactivation in HBs antigen-positive patients.
- A grading of HBV reactivation risk and management recommendations were developed for common anticancer drugs.
Conclusions:
- HBV screening before initiating systemic treatment is recommended.
- Pre-emptive antiviral treatment can effectively reduce HBV reactivation risk and prevent chemotherapy interruptions.
More Related Videos
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Related Concept Videos
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Mechanisms of Retrovirus-induced Cancers
Treatment Resistant Cancers
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...